Patent intelligence · US
US 12201596
Levodopa dosing regimen
Levodopa dosing regimen
Patent details — US 12201596
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 21, 2025
- Expiration
- Jan 16, 2045
- Applicant
- AMNEAL PHARMACEUTICALS LLC
- Claims
- 17
- CPC classes
- A61K, A61K31/198, A61K9/4825, A61K9/5005
Quick answer
US 12201596 (Levodopa dosing regimen) is held by AMNEAL PHARMACEUTICALS LLC. Status: granted. Granted Jan 21, 2025. Expires Jan 16, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMNEAL PHARMACEUTICALS LLC
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/198, A61K9/4825, A61K9/5005, A61K9/5026, A61K9/5073
More from AMNEAL PHARMACEUTICALS LLC
Related pharmaceutical patents in our USPTO index.
-
US 12383522
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
granted -
US 12370163
Levodopa dosing regimen
granted -
US 12303482
Levodopa dosing regimen
granted -
US 12303481
Levodopa dosing regimen
granted -
US 12295931
Levodopa dosing regimen
granted -
US 12263149
Levodopa dosing regimen
granted -
US 12263148
Levodopa dosing regimen
granted -
US 12233166
Extended release compositions comprising pyridostigmine
granted
Frequently asked questions
What is US patent 12201596?
US 12201596 (Levodopa dosing regimen) is held by AMNEAL PHARMACEUTICALS LLC. Status: granted. Granted Jan 21, 2025. Expires Jan 16, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12201596?
AMNEAL PHARMACEUTICALS LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 32 pharmaceutical patents for this assignee.
When does US 12201596 expire?
Our index shows an expiration date of Jan 16, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.